Skip to content
My WebMD Sign In, Sign Up
Promising Early Results on Lupus Treatment
avatar
R Swamy Venuturupalli, MD, FACR posted:
This is an novel treatment strategy that involves blocking toll like receptors. There is good research to suggest that in Lupus Toll like receptors are inappropriately activated by anti-nuclear antibodies which are complexed with self RNA or DNA. Blocking Toll like receptors may help prevent the immune activation and resultant inflammatory response. In fact, there is good evidence that medications such as plaquenil, which have been in use for lupus for decades act via their effects on toll like receptors. This new generation of toll like receptor blockers (there are a few of these medications currently in clinical trials) promise to be better and potentially safer, which is why they are interesting. Of course, the information that is highlighted in this particular report is still very early in testing and it remains to be seen if the effects can be maintained in human trials.
Was this Helpful?
4 of 4 found this helpful
Reply
 
avatar
K2isKsquared responded:
Dr Venuturupalli,

Thanks so much for posting this!! It's nice to know someone is thinking of us and working toward a cure.

K2


Featuring Experts

Dr. R. Swamy Venuturupalli is a board-certified rheumatologist practicing in Los Angeles. He is Clinical Chief of the Division of Rheumatology at Ce...More

Coping
With Lupus

WebMD's Day2Night will help you develop personal coping strategies for living with lupus – at home,
at work, or with family
and friends.
Visit Lupus Day2Night

Helpful Tips

StressExpert
There is a big connection between stress and lupus. Although it doesn't actually cause lupus, it certainly exacerbates it. An article from ... More
Was this Helpful?
14 of 14 found this helpful

Related Drug Reviews

  • Drug Name User Reviews

Report Problems to the
Food and Drug Administration

FDAYou are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.